
OCCUPATION AND HEALTH ›› 2026, Vol. 42 ›› Issue (16): 2189-2193.
• Treatise—Occupational Health and Occupational Diseases • Previous Articles Next Articles
Received:2025-09-17
Revised:2025-10-10
Online:2026-08-15
Published:2026-08-10
Contact:
CHEN Yaohua,E-mail:CLC Number:
ZHANG Yan, CHEN Yaohua. Clinical application analysis of selected serum biomarkers in the diagnosis of silicosis. [J]OCCUPATION AND HEALTH, 2026, 42(16): 2189-2193.
| 组别 | 人数 | 年龄 [($\bar{x}±s$)岁] | 高血压 [例(%)] | 糖尿病 [例(%)] | 吸烟 [例(%)] |
|---|---|---|---|---|---|
| 矽肺组 | 499 | 66.81±0.42 | 122(24.4) | 48(9.6) | 200(40.1) |
| 观察组 | 154 | 65.97±0.67 | 41(26.6) | 4(2.6) | 58(37.7) |
| χ2/t值 | 0.997a | 0.270b | 7.980b | 0.281b | |
| P值 | 0.319 | 0.600 | 0.005 | 0.596 |
| 组别 | 人数 | 年龄 [($\bar{x}±s$)岁] | 高血压 [例(%)] | 糖尿病 [例(%)] | 吸烟 [例(%)] |
|---|---|---|---|---|---|
| 矽肺组 | 499 | 66.81±0.42 | 122(24.4) | 48(9.6) | 200(40.1) |
| 观察组 | 154 | 65.97±0.67 | 41(26.6) | 4(2.6) | 58(37.7) |
| χ2/t值 | 0.997a | 0.270b | 7.980b | 0.281b | |
| P值 | 0.319 | 0.600 | 0.005 | 0.596 |
| 组别 | 人数 | 总胆红素 (umol/L) | 直接胆红素 (umol/L) | 间接胆红素 (umol/L) | 肌酐(umol/L) | 尿素 (umol/L) | MCHC(g/L) | NLR | PLR | 血红蛋白(g/L) |
|---|---|---|---|---|---|---|---|---|---|---|
| 矽肺组 | 499 | 11.1(7.9,15.6) | 3.3(2.4,4.6) | 7.6(5.4,11.3) | 75.6(66.0,87.0) | 6.2(4.9,7.9) | 323.0(314.8,333.0) | 3.4(2.4,5.3) | 126.3(86.2,182.6) | 134.0(122.0,145.0) |
| 对照组 | 154 | 11.6(8.9,14.8) | 3.1(2.3,3.51) | 8.7(6.3,10.9) | 70.9(62.7,81.0) | 5.6(4.9,6.8) | 320.0(313.8,329.0) | 2.3(1.7,3.0) | 76.5(58.8,118.7) | 145.0(136.0,155.0) |
| Z值 | -0.119 | -3.503 | -1.077 | -3.420 | -3.168 | -1.948 | -8.760 | -8.757 | -8.713 | |
| P值 | 0.905 | <0.001 | 0.281 | <0.001 | 0.002 | 0.051 | <0.001 | <0.001 | <0.001 |
| 组别 | 人数 | 总胆红素 (umol/L) | 直接胆红素 (umol/L) | 间接胆红素 (umol/L) | 肌酐(umol/L) | 尿素 (umol/L) | MCHC(g/L) | NLR | PLR | 血红蛋白(g/L) |
|---|---|---|---|---|---|---|---|---|---|---|
| 矽肺组 | 499 | 11.1(7.9,15.6) | 3.3(2.4,4.6) | 7.6(5.4,11.3) | 75.6(66.0,87.0) | 6.2(4.9,7.9) | 323.0(314.8,333.0) | 3.4(2.4,5.3) | 126.3(86.2,182.6) | 134.0(122.0,145.0) |
| 对照组 | 154 | 11.6(8.9,14.8) | 3.1(2.3,3.51) | 8.7(6.3,10.9) | 70.9(62.7,81.0) | 5.6(4.9,6.8) | 320.0(313.8,329.0) | 2.3(1.7,3.0) | 76.5(58.8,118.7) | 145.0(136.0,155.0) |
| Z值 | -0.119 | -3.503 | -1.077 | -3.420 | -3.168 | -1.948 | -8.760 | -8.757 | -8.713 | |
| P值 | 0.905 | <0.001 | 0.281 | <0.001 | 0.002 | 0.051 | <0.001 | <0.001 | <0.001 |
| 自变量 | β值 | $s_{\bar{x}}$ | Wald χ2值 | P值 | OR值 | 95%CI |
|---|---|---|---|---|---|---|
| 糖尿病 | -9.410 | 0.696 | 1.830 | 0.176 | 0.390 | 0.100~1.526 |
| 吸烟史 | -1.629 | 0.302 | 29.017 | <0.001 | 0.196 | 0.108~0.355 |
| 直接胆红素 | 0.291 | 0.103 | 7.979 | 0.005 | 1.338 | 1.093~1.637 |
| 肌酐 | 0.023 | 0.010 | 5.310 | 0.021 | 1.023 | 1.003~1.004 |
| 尿素 | 0.015 | 0.098 | 0.023 | 0.878 | 1.015 | 0.838~1.229 |
| NLR | -1.058 | 0.163 | 42.235 | <0.001 | 0.347 | 0.252~0.477 |
| PLR | 0.450 | 0.005 | 86.386 | <0.001 | 1.046 | 1.036~1.056 |
| 血红蛋白 | -0.060 | 0.011 | 29.585 | <0.001 | 0.941 | 0.921~0.962 |
| 自变量 | β值 | $s_{\bar{x}}$ | Wald χ2值 | P值 | OR值 | 95%CI |
|---|---|---|---|---|---|---|
| 糖尿病 | -9.410 | 0.696 | 1.830 | 0.176 | 0.390 | 0.100~1.526 |
| 吸烟史 | -1.629 | 0.302 | 29.017 | <0.001 | 0.196 | 0.108~0.355 |
| 直接胆红素 | 0.291 | 0.103 | 7.979 | 0.005 | 1.338 | 1.093~1.637 |
| 肌酐 | 0.023 | 0.010 | 5.310 | 0.021 | 1.023 | 1.003~1.004 |
| 尿素 | 0.015 | 0.098 | 0.023 | 0.878 | 1.015 | 0.838~1.229 |
| NLR | -1.058 | 0.163 | 42.235 | <0.001 | 0.347 | 0.252~0.477 |
| PLR | 0.450 | 0.005 | 86.386 | <0.001 | 1.046 | 1.036~1.056 |
| 血红蛋白 | -0.060 | 0.011 | 29.585 | <0.001 | 0.941 | 0.921~0.962 |
| 生物标志物 | 截断值 | 灵敏度 | 特异度 | AUC | 95%CI |
|---|---|---|---|---|---|
| 直接胆红素 | 3.690 | 0.402 | 0.810 | 0.590 | 0.640~0.546 |
| 肌酐 | 82.750 | 0.334 | 0.818 | 0.592 | 0.640~0.544 |
| NLR | 2.920 | 0.630 | 0.740 | 0.733 | 0.774~0.692 |
| PLR | 83.550 | 0.775 | 0.591 | 0.731 | 0.775~0.687 |
| 血红蛋白 | 175.000 | 0.012 | 0.994 | 0.288 | 0.331~0.245 |
| 联合预测概率 | 0.667 | 0.929 | 0.862 | 0.834~0.890 |
| 生物标志物 | 截断值 | 灵敏度 | 特异度 | AUC | 95%CI |
|---|---|---|---|---|---|
| 直接胆红素 | 3.690 | 0.402 | 0.810 | 0.590 | 0.640~0.546 |
| 肌酐 | 82.750 | 0.334 | 0.818 | 0.592 | 0.640~0.544 |
| NLR | 2.920 | 0.630 | 0.740 | 0.733 | 0.774~0.692 |
| PLR | 83.550 | 0.775 | 0.591 | 0.731 | 0.775~0.687 |
| 血红蛋白 | 175.000 | 0.012 | 0.994 | 0.288 | 0.331~0.245 |
| 联合预测概率 | 0.667 | 0.929 | 0.862 | 0.834~0.890 |
| [1] | 樊乃根. 矽肺发病及治疗研究的最新进展[J]. 职业与健康, 2016, 32(8):1140-1142. |
| [2] | 刘贵钱, 张晓华, 李颖. 肌成纤维细胞对矽肺发病及治疗的研究进展[J]. 职业与健康, 2020, 36(17):2445-2448. |
| [3] |
LEUNG C C, YU I T, CHEN W. Silicosis[J]. Lancet, 2012, 379(9830):2008-2018.
DOI PMID |
| [4] | 庞勇, 潘力平, 唐煌, 等. 四川省江油市矽肺流行病学和影像学特征及其与矽肺分期的关联性[J]. 职业与健康, 2020, 36(2):161-164. |
| [5] |
HOY R F, CHAMBERS D C. Silica-related diseases in the modern world[J]. Allergy, 2020, 75(11):2805-2817.
DOI URL |
| [6] |
PANDEY J K, AGARWAL D. Biomarkers:A potential prognostic tool for silicosis[J]. Indian J Occup Environ Med, 2012, 16(3):101-107.
DOI URL |
| [7] | 贺今, 王贝贝, 邱梦茹, 等. 矽肺患者合并阻塞性睡眠呼吸暂停低通气综合征的临床特征分析[J]. 职业与健康, 2024, 40(15):2017-2020. |
| [8] | FUKUSHIMA K, UCHIDA H A, FUCHIMOTO Y, et al. Silica-associated systemic lupus erythematosus with lupus nephritis and lupus pneumonitis:A case report and a systematic review of the literature[J]. Medicine(Baltimore), 2022, 101(7):e28872. |
| [9] |
MOROTTI A, SOLLAKU I, CATALANI S, et al. Systematic review and meta-analysis of epidemiological studies on the association of occupational exposure to free crystalline silica and systemic lupus erythematosus[J]. Rheumatology(Oxford), 2021, 60(1):81-91.
DOI URL |
| [10] |
MÖHNER M, POHRT A, GELLISSEN J. Occupational exposure to respirable crystalline silica and chronic non-malignant renal disease:systematic review and meta-analysis[J]. Int Arch Occup Environ Health, 2017, 90(7):555-574.
DOI |
| [11] | 张元元, 王驰, 黄华, 等. 黄芩苷基于矽肺模型大鼠的肝肾毒性作用研究[J]. 职业与健康, 2021, 37(12):1619-1621,1626. |
| [12] |
BARNES H, GOH N S L, LEONG T L, et al. Silica-associated lung disease:An old-world exposure in modern industries[J]. Respirology, 2019, 24(12):1165-1175.
DOI URL |
| [13] |
LI J, YIN P, WANG H, et al. The burden of pneumoconiosis in China:an analysis from the Global Burden of Disease Study 2019[J]. BMC Public Health, 2022, 22(1):1114.
DOI |
| [14] | 杨阳. 152例矽肺并发症的临床分析[J]. 中国工业医学杂志, 2013, 26(3):188-189. |
| [15] |
HOWLETT P, GAN J, LESOSKY M, et al. Relationship between cumulative silica exposure and silicosis:A systematic review and dose-response meta-analysis[J]. Thorax, 2024, 79(10):934-942.
DOI URL |
| [16] |
HANDRA C M, GURZU I L, CHIRILA M, et al. Silicosis:New challenges from an old inflammatory and fibrotic disease[J]. Front Biosci (Landmark Ed), 2023, 28(5):96.
DOI URL |
| [17] | 毛翎. 《尘肺病治疗中国专家共识(2024年版)》解读[J]. 环境与职业医学, 2024, 41(1):22-24. |
| [18] |
MORIN L, LECUREUR V, LESCOAT A. Results from omic approaches in rat or mouse models exposed to inhaled crystalline silica:a systematic review[J]. Part Fibre Toxicol, 2024, 21(1):10.
DOI |
| [19] |
ADAMCAKOVA J, MOKRA D. New insights into pathomechanisms and treatment possibilities for lung silicosis[J]. Int J Mol Sci, 2021, 22(8):4162.
DOI URL |
| [20] |
SUBRA J F, RENIER G, REBOUL P, et al. Lymphopenia in occupational pulmonary silicosis with or without autoimmune disease[J]. Clin Exp Immunol, 2001, 126(3):540-544.
PMID |
| [21] |
GOUDIE A S. Desert dust and human health disorders[J]. Environ Int, 2014, 63:101-113.
DOI PMID |
| [22] |
KOUPENOVA M, CLANCY L, CORKREY H A, et al. Circulating platelets as mediators of immunity,inflammation,and thrombosis[J]. Circ Res, 2018, 122(2):337-351.
DOI URL |
| [23] |
OCANA A, NIETO-JIMENEZ C, PANDIELA A, et al. Neutrophils in cancer:Prognostic role and therapeutic strategies[J]. Mol Cancer, 2017, 16(1):137.
DOI URL |
| [24] |
GASPARYAN A Y, AYVAZYAN L, MUKANOVA U, et al. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases[J]. Ann Lab Med, 2019, 39(4):345-357.
DOI PMID |
| [25] |
GARCIA-NUNEZ A, JIMENEZ-GOMEZ G, HIDALGO-MOLINA A, et al. Inflammatory indices obtained from routine blood tests show an inflammatory state associated with disease progression in engineered stone silicosis patients[J]. Sci Rep, 2022, 12(1):8211.
DOI |
| [26] | WANG M, ZHANG Z, LIU J, et al. Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis:A multi-omics study with drug exploration[J]. Signal Transduct Target Ther, 2022, 7(1):157. |
| [27] | PENG Y F, DENG J H, HUANG X Y, et al. Serum bilirubin levels and disease severity in patients with pneumoconiosis[J]. Can Respir J, 2023, 2023:5642040. |
| [28] |
NAKASHIMA K, SATO T, SHIGEMORI S, et al. Regulatory role of heme oxygenase-1 in silica-induced lung injury[J]. Respir Res, 2018, 19(1):144.
DOI |
| [29] |
HINDS T D J R, STEC D E. Bilirubin,a cardiometabolic signaling molecule[J]. Hypertension, 2018, 72(4):788-795.
DOI URL |
| [30] |
WEI C H, LI C H, SHEN T C, et al. Risk of chronic kidney disease in pneumoconiosis:Results from a tetrospective vohort study(2008-2019)[J]. Biomedicines, 2023, 11(1):150.
DOI URL |
| [31] | SASAI F, ROGERS K L, ORICHY D J, et al. Inhaled silica nanoparticles cause chronic kidney disease in rats[J]. Am J Physiol Renal Physiol, 2022, 323(1):F48-F58. |
| [32] | GHAHRAMANI N. Silica nephropathy[J]. Int J Occup Environ Med, 2010, 1(3):108-115. |
| [33] | 陈彦龙, 何江, 马兰. 263例煤工尘肺患者血液红细胞数及血红蛋白值分析[J]. 北方药学, 2013, 10(10):133-134. |
| [34] |
RUAN Z, LI D, HU Y, et al. The association between mean corpuscular hemoglobin concentration and prognosis in patients with acute pulmonary embolism:A retrospective cohort study[J]. Clin Appl Thromb Hemost, 2022, 28:10760296221103867.
DOI URL |
| [35] |
HESSEL P A, GAMBLE J F, NICOLICH M. Relationship between silicosis and smoking[J]. Scand J Work Environ Health, 2003, 29(5):329-336.
DOI URL |
| [36] | LI T, YANG X Y, XU H, et al. Early identification,accurate diagnosis,and treatment of silicosis[J]. Can Respir J, 2022, 2022:3769134. |
| [37] |
KREFFT S, WOLFF J, ROSE C. Silicosis:An update and guide for clinicians[J]. Clin Chest Med, 2020, 41(4):709-722.
DOI URL |
| [38] |
DU S, LI C, LU Y, et al. Dioscin alleviates crystalline silica-induced pulmonary inflammation and fibrosis through promoting alveolar macrophage autophagy[J]. Theranostics, 2019, 9(7):1878-1892.
DOI PMID |
| [39] | 蒋恩霏, 储卫忠, 商维维, 等. 2012-2021年四川省新发矽肺病例流行病学特征分析[J]. 预防医学情报杂志, 2023, 39(5):481-486,492. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
